Jansen, J., et al. Adjuvants MPLA and SMNP induce antiviral immunity and indirectly revert HIV-1 latency. PLoS One, 2026 Jul 20, 21(7):e0348959. PMID: 42475333

This paper is a significant contribution to the field of saponin-based adjuvants, particularly highlighting the potent immunostimulatory capacity of the saponin-MPLA nanoparticle adjuvant (SMNP) compared to MPLA alone. It demonstrates that SMNP, by combining TLR4 activation with inflammasome stimulation through saponin components like QS-21, elicits a more robust cytokine response and can indirectly reverse HIV-1 latency ex vivo, even in ART-treated individuals. 

The study provides mechanistic insight into how saponin-based nanoparticle adjuvants not only enhance immune activation but also modulate the HIV reservoir, positioning SMNP as a promising candidate for therapeutic HIV vaccination. This work underscores the potential of integrating saponin adjuvants into cure strategies, emphasizing their dual role in immune potentiation and latency reversal, and advancing the design of more effective adjuvants for infectious diseases.

Click here to access the full scientific paper.